Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues

Journal of Experimental & Clinical Cancer Research

Ke Wang⁴  Leslie C Sutherland¹  Wei Xu⁴  Lijing Zhao²  Chen Shao²  Jie Zhang⁴  Hong Liang³ 

[1] Research Program, Northeast Cancer Centre, Health Sciences North/Horizon Santé-Nord, Sudbury, Ontario, P3E 5J1, Canada;Department of pathophysiology, Norman Bethune College of Medicine of Jilin University, Changchun, Jilin, 130021, China;Department of Respiratory Medicine, Changchun General Hospital, Changchun, Jilin, China;Department of Respiratory Medicine, Second Affiliated Hospital of Jilin University, Changchun, Jilin, 130041, China

关键词: carcinogenesis;    KRAS;    EGFR;    RBM5;    NSCLC;   

Others  :  826589
DOI  :  10.1186/1756-9966-31-36

 received in 2012-02-07, accepted in 2012-04-26,  发布年份 2012

【 摘 要 】

Background

RNA binding motif 5 (RBM5) is a tumor suppressor gene that modulates apoptosis through the regulation of alternative splicing of apoptosis-related genes. This study aimed to detect RBM5 expression in non-small cell lung cancer (NSCLC) and to associate RBM5 expression with clinicopathological data from NSCLC patients and EGFR and KRAS expression to better understand the potential role of RBM5 in NSCLC.

Method

Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were performed to detect expression of mRNA and protein, respectively, of RBM5, EGFR and KRAS in 120 paired non-tumor and tumor samples of NSCLC.

Results

The data showed that expression of RBM5 mRNA and protein was significantly reduced in NSCLC compared to normal tissues, whereas expression of both EGFR and KRAS genes was increased in NSCLC compared to normal tissues. Furthermore, the reduced RBM5 protein expression correlated with smoking status, tumor stage and lymph node metastasis of NSCLC, while overexpression of EGFR and KRAS proteins correlated with tumor stage and lymph node metastasis of NSCLC. Overexpression of KRAS protein was more frequent in smokers with NSCLC. In addition, expression of RBM5 mRNA and protein was negatively correlated with expression of EGFR and KRAS mRNA and protein in NSCLC tissues.

Conclusion

This study suggests further evaluation of RBM5 expression is warranted for use of RBM5 as a biomarker for NSCLC patients.

【 授权许可】

   
2012 Liang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000, 18:106-115.
• [2]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
• [3]Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA: Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003, 163:1949-1960.
• [4]Hui HP: Population-based differences in treatment outcome following anticancer drug therapies. Lancet 2010, 11:75-84.
• [5]Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
• [6]Wang L, Xiong Y, Sun Y, Fang Z, Li L, Ji H, Shi T: HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res 2010, 38:665-669.
• [7]Herbst RS, Heymach JV, Lippman SM: Molecular origins of cancer: lung cancer. N Engl J Med 2008, 359:1367-1380.
• [8]Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C: Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2010, 10:1-13.
• [9]Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl JMed 2008, 358:1160-1174.
• [10]Hirsch FR, Varella-Garcia M, Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer Predictive value of EGFR/HER2. Oncogene 2009, 28:32-37.
• [11]Costa DB, Schumer ST, Tenen DG, Kobayashi S: Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008, 26:1182-1186.
• [12]Suda K, Tomizawa K, Mitsudomi T: Biological and clinical significance of KRAS mutations in lung cancer: and oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010, 29:49-60.
• [13]Heidorn SJ, Milagre V, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R: Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell 2010, 1:209-221.
• [14]Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Canc Genet Cytogenet 2007, 173:107-113.
• [15]Wei MH, Latif F, Bader S, Kashuba V, Chen JY, Duh FM, Sekido Y, Lee CC, Geil L, Kuzmin I, Zabarovsky E, Klein G, Zbar B, Minna JD, Lerman MI: Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res 1996, 56:1487-1492.
• [16]Oh JJ, Razfar A, Delgado I, Reed RA, Malkina A, Boctor B, Slamon DJ: 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res 2006, 66:3419-3427.
• [17]Ji L, Minna JD, Roth JA: 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol 2005, 1(1):79-92.
• [18]Sutherland LC, Wang K, Robinson AG: RBM5 as a Putative Tumor Suppressor Gene for Lung Cancer. J Thorac Oncol 2010, 5:294.
• [19]Rintala-Maki ND, Goard CA, Langdon CE, Wall VE, Traulsen KE, Morin CD, Bonin M, Sutherland LC: Expression of RBM5-related factors in primary breast tissue. J Cell Biochem 2007, 100:1440-1458.
• [20]Edamatsu H, Kaziro Y, Itoh H: LUCA15, a putative tumour suppressor gene encoding an RNA-bindingnuclear protein, is down-regulated in ras-transformedRat-1 cells. Genes Cells 2000, 5:849-858.
• [21]Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2007, 2(8):706-714.
• [22]Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ: Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005, 11:6333-6341.
• [23]Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS: cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002, 23:736-748.
• [24]Oh JJ, West AR, Fishbein MC, Slamon DJ: A candidate tumour suppressor gene, H37, from the human lung cancer tumour suppressor locus 3p21.3. Cancer Res 2002, 62:3207-3213.
• [25]Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecualr signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
• [26]Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET: Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT transgenic mice: correlation to human disease. Cancer Res 2004, 64:5973-5981.
• [27]Oh JJ, Taschereau EO, Koegel AK, Ginther CL, Rotow JK, Isfahani KZ, Slamon DJ: RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer 2010, 70:253-262.
• [28]Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
• [29]Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, Yousem SA: Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006, 125:860-865.
• [30]Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA: Varella-Garcia M: Epidermal growth factor receptor gene and protein andgefitinib sensitivity in non-small-cell lung cancer. J Natl Canc Inst 2005, 97:643-655.
• [31]Sutherland LC, Wang K, Robinson AG: RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol 2010, 5:294-298.